Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.450
-0.040 (-2.68%)
At close: Apr 28, 2026, 4:00 PM EDT
1.290
-0.160 (-11.03%)
Pre-market: Apr 29, 2026, 8:44 AM EDT
Rein Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 10.9 | 13.86 | 11.36 | 9.68 | 9.6 | |
| Research & Development | 11.03 | 14.25 | 3.99 | 17.97 | 17.01 | |
| Operating Expenses | 21.93 | 28.11 | 15.35 | 27.65 | 26.61 | |
| Operating Income | -21.93 | -28.11 | -15.35 | -27.65 | -26.61 | |
| Interest & Investment Income | - | 0.7 | 0.6 | - | - | |
| Other Non Operating Income (Expenses) | 0.05 | -0.02 | -0.09 | 0.32 | -0.01 | |
| EBT Excluding Unusual Items | -21.88 | -27.43 | -14.84 | -27.33 | -26.62 | |
| Merger & Restructuring Charges | - | - | -0.93 | - | - | |
| Gain (Loss) on Sale of Assets | - | - | 0.04 | - | 0.07 | |
| Asset Writedown | -28.7 | -37 | - | - | - | |
| Other Unusual Items | - | - | - | - | 0.39 | |
| Pretax Income | -50.58 | -64.43 | -15.73 | -27.33 | -26.16 | |
| Income Tax Expense | -0.71 | -1.54 | - | - | - | |
| Net Income | -49.87 | -62.88 | -15.73 | -27.33 | -26.16 | |
| Net Income to Common | -49.87 | -62.88 | -15.73 | -27.33 | -26.16 | |
| Shares Outstanding (Basic) | 25 | 18 | 5 | 5 | 4 | |
| Shares Outstanding (Diluted) | 25 | 18 | 5 | 5 | 4 | |
| Shares Change (YoY) | 41.84% | 290.09% | 1.31% | 2.23% | 154.70% | |
| EPS (Basic) | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | |
| EPS (Diluted) | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | |
| Free Cash Flow | -19.36 | -22.29 | -19.81 | -24.87 | -23.91 | |
| Free Cash Flow Per Share | -0.76 | -1.24 | -4.31 | -5.48 | -5.38 | |
| EBITDA | -21.93 | -28.05 | -15.23 | -27.48 | -26.48 | |
| D&A For EBITDA | 0 | 0.06 | 0.12 | 0.17 | 0.12 | |
| EBIT | -21.93 | -28.11 | -15.35 | -27.65 | -26.61 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.